or seborrheic dermatitis–like morphology) and can occur with normal levels of total and allergen-specific serum immunoglobulin E in about a third of cases. Adult AD is mainly mild to moderate ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The point prevalence of atopic dermatitis was highest in those aged 0 to 5 years among children and adolescents and in those aged 18 to 59 years among adults. The estimated global point prevalence ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

The substantial correlation between prurigo nodularis (PN) and atopic dermatitis (AD) has been highlighted by a recent ...

Considering the frequent use of oral corticosteroids among adults with AD and the potential ... and safety outcomes for patients with atopic dermatitis" JAMA Netw Open. 2024; DOI: 10.1001 ...